Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
-0.48 (-1.03%)
Real-time:   1:37PM EST
NYSE real-time data - Disclaimer
Currency in USD
Range 45.75 - 47.25
52 week 27.94 - 47.37
Open 47.11
Vol / Avg. 160,716.00/575,384.00
Mkt cap 1.91B
P/E 28.87
Div/yield     -
EPS 1.60
Shares 41.38M
Beta 1.29
Inst. own 91%
Feb 21, 2018
Q4 2017 Emergent BioSolutions Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 14, 2017
Emergent BioSolutions Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
Dec 7, 2017
Emergent BioSolutions Inc Analyst & Investor Day - Webcast
Nov 29, 2017
Emergent BioSolutions Inc at Piper Jaffray Healthcare Conference
Nov 15, 2017
Emergent BioSolutions Inc at Three Part Advisors Southwest IDEAS Investor Conference
Nov 2, 2017
Q3 2017 Emergent BioSolutions Inc Earnings Call - Webcast
Nov 2, 2017
Q3 2017 Emergent BioSolutions Inc Earnings Release
Sep 25, 2017
Emergent BioSolutions Inc at Cantor Fitzgerald Global Healthcare Conference - Webcast
Sep 20, 2017
Emergent BioSolutions Inc at Singular Research Chicago Midwestern Values
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 22.45% 12.79%
Operating margin 31.97% 21.59%
EBITD margin - 29.41%
Return on average assets 13.49% 6.23%
Return on average equity 20.96% 9.95%
Employees 1,098 -
CDP Score - -


400 Professional Dr Ste 400
United States - Map
+1-240-6313200 (Phone)
+1-240-6313203 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Daniel J. Abdun-Nabi President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Chief Financial Officer, Executive Vice President, Administration, Treasurer
Age: 59
Bio & Compensation  - Reuters
Adam Havey Executive Vice President - Business Operations
Age: 46
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Jerome M. Hauer Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
George A. Joulwan USA Independent Director
Age: 77
Bio & Compensation  - Reuters